BioSpace News Archive

$8 million investment, including new building & FDA-approved vacuum plasma spray (VPS) equipment, enhances in-house coating and single-source orthopedic implant capabilities

Analysis Shows Treatment Effect of Omecamtiv Mecarbil Increased Progressively as Baseline Ejection Fraction Decreased

Prometheus Biosciences, Inc., a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease, announced the appointment of Fred Hassan to its Board of Directors.

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, and Antengene Corporation, Ltd. (SEHK: 6996.HK), a leading clinical-stage R&D driven biopharmaceutical company focused on innovative medicines for oncology and other life-threatening diseases

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on developing compounds that activate Tie2, reported financial results for the first quarter ended March 31, 2021 and provided a business update.

Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, reports financial results for the three months ended March 31, 2021 and provides updates on its antiviral pipeline and business activities.

Astellas’ ambitious innovation and committed collaboration support new research on investigational and approved therapies in hard-to-treat cancers

CIGC’s Director of Research Discusses Fibroids, Endometriosis and Treating the Coexistence of Both Conditions at an Ambulatory Surgery Center

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a drug discovery service agreement with Anavo Therapeutics. Under the terms of the agreement, Vipergen will apply its proprietary high-fidelity DNA-encoded library